Umang Swami: Prior NHT in patients with MCRPC

Umang Swami, Assistant Professor in the Department of Oncology at Huntsman Cancer Institute, shared on X:

“Most patients (63%) diagnosed with Metastatic castration-resistant prostate cancer (mCRPC) (even in 2023) never received prior Neoadjuvant hormonal therapy (NHT). .

NHT remains the most common therapy in 1L mCRPC (even in patients treated with prior NHT).”

Source: Umang Swami/X